MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis

Company Overview

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for inflammatory and immunologic diseases. The company is headquartered in Zug, Switzerland, and its ordinary shares trade on the Nasdaq under the symbol MLTX.

MoonLake’s primary product candidate is sonelokimab, a novel Nanobody-based inhibitor designed to selectively target interleukin-17A and interleukin-17F, two cytokines involved in inflammation. The company is evaluating sonelokimab in conditions including hidradenitis suppurativa, psoriatic arthritis and axial spondyloarthritis, with the goal of addressing significant unmet needs in chronic inflammatory disease.

MoonLake was established to advance sonelokimab and related immunology programs and has developed its business around a Nanobody-based drug-development platform. The company’s activities are focused primarily on clinical development and regulatory preparation rather than commercialized products, and its programs are intended for patients in international markets where inflammatory diseases are prevalent.

Key Stats

• Today's Range: $11.03 to $11.65
• 50-Day Range: $11.41 to $19.88
• 52-Week Range: $7.50 to $23.29
• Volume: 1.83 million shs
• Average Volume: 1.76 million shs
• Market Capitalization: $971.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.50
• Consensus Rating: Hold

MoonLake Immunotherapeutics Stock Analysis - MarketRank™

MoonLake Immunotherapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 553rd out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

MoonLake Immunotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 9 buy ratings, 2 hold ratings, and 3 sell ratings.

Upside Potential

MoonLake Immunotherapeutics has a consensus price target of $28.50, representing about 149.8% upside from its current price of $11.41.

Amount of Analyst Coverage

MoonLake Immunotherapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($3.34) to ($3.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MoonLake Immunotherapeutics is -2.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MoonLake Immunotherapeutics is -2.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MoonLake Immunotherapeutics has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.73% of the float of MoonLake Immunotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

MoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 6.07.

Change versus previous month

Short interest in MoonLake Immunotherapeutics has recently increased by 25.24%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MoonLake Immunotherapeutics does not currently pay a dividend.

Dividend Growth

MoonLake Immunotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.67

News Sentiment

MoonLake Immunotherapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for MoonLake Immunotherapeutics this week, compared to 10 articles on an average week.

Search Interest

Only 1 people have searched for MLTX on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

MarketBeat Follows

2 people have added MoonLake Immunotherapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, MoonLake Immunotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,947,138.00 in company stock.

Percentage Held by Insiders

10.40% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

93.85% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MLTX
• CIK: 1821586
• Web: www.moonlaketx.com
• Phone: 41-41-510-8022
• Fax: N/A
• Employees: 130
• Year Founded: N/A

Price Target and Rating

• Average Price Target for MoonLake Immunotherapeutics: $28.50
• High Price Target: $50.00
• Low Price Target: $10.00
• Potential Upside/Downside: +149.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$227.32 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -82.53%
• Return on Assets: -58.17%

Debt

• Debt-to-Equity Ratio: 0.23
• Current Ratio: 12.56
• Quick Ratio: 12.56

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.27 per share
• Price / Book: 2.67

Miscellaneous

• Outstanding Shares: 85,110,000
• Free Float: 76,256,000
• Market Cap: $971.11 million
• Optionable: Optionable
• Beta: 1.08